Facebook Linkedin Instagram Youtube
Best PET Scan in Rohtak
Menu

RNM Imaging, Therapy & Research Center- Advanced Theranostics Center

RNM-Care That’s Ethical, Advanced & Personalized “We know these therapies don’t just prolong lives-they restore dignity, reduce suffering, and bring peace to families of cancer patients. That’s why we’re here.” We look forward to giving patients access to advanced, accessible and compassionate radionuclide therapies close to home in very personalized setting away from very busy corporate and government settings.
download brochure

RNM is the first comprehensive dedicated nuclear medicine and theranostic center in Rohtak, Haryana to offer dedicated, advanced nuclear medicine services, including advanced precise- targeted radionuclide therapy for oncology and endocrine indications. Led by AIIMS and PGIMER-trained specialists, RNM emphasizes evidence-based protocols and compassionate care, providing accessible treatments away from crowded metropolitan hospitals.

Vision

To provide nuclear medicine facilities in the hinterlands, bringing world-class, ethical services to patients without the need to travel to metropolitan areas.

Expertise:

Highly qualified professional team of AIIMS and PGIMER trained doctors led by Dr. Parveen Kundu, MBBS (AIIMS), MD (Nuclear Medicine, AIIMS), FANMB with over 15 years of nuclear medicine and therapy experience. A team of highly qualified professionals- physicists, technologist and nurses committed to delivering personalized radionuclide therapies.

Approved Radionuclide Therapies Offered At Rnm Center:

LUTETIUM-177 PSMA-617 THERAPY

Indications:

  • FDA Approved (2022) for mCRPC post-AR therapy and taxane chemotherapy
  • Now supported for pre-chemotherapy settings based on recent evidence Supporting Trials:

Vision Trial (Nejm 2021)

VISION Trial (NEJM 2021)

  • 38% reduction in risk of death
  • Improved radiographic progression-free survival

PSMAfore Trial (2023, ASCO & ESMO)

  • Showed significant delay in disease progression in mCRPC patients before taxane chemotherapy
  • Median rPFS: 7.4 vs 3.4 months (Lu-177 PSMA vs ARPI switch)

Patient Selection:

  • PSMA PET-positive metastatic prostate cancer
  • Failed prior AR inhibitors (e.g., enzalutamide, abiraterone)
  • Either pre- or post-taxane chemotherapy status.
PET scan cost in Rohtak

Led by AIIMS and PGIMER-trained specialists

with over 15 years of dedicated experience in radionuclide therapy.

PET scan in Rohtak

One Of The Few Specialized Theranostic Centers In North India

located in Haryana for maximum accessibility.
PET scan in Rohtak

No Need To Travel
To Big Cities

we eliminate long journeys, crowded hospitals, and excessive waiting times.
PET scan in Rohtak

Ethical, High-quality,
And Personalized Care

delivered with integrity and compassion.
PET scan in Rohtak

Patient-First
Approach

with individualized treatment protocols and detailed follow-ups.
PET scan in Rohtak

Special Financial Assistance Programs

for underprivileged patients-because these therapies change lives, not just for the patient, but their entire family.
PET scan in Rohtak

Integrated Team-based Model

with timely updates to referring doctors and coordinated care pathways.
PET scan in Rohtak

Advanced Imaging Capabilities including

including PSMA PET/CT, DOTA PET/CT, and SPECT/CT for accurate staging, therapy planning, and follow-up.
PET scan in Rohtak

Assisted Travelling Plans

with pick and drop facilities to nearest airport and railway station [ 1.5 hrs away from international airport]

Key Radiopharmaceuticals:

[161Tb]Tb-PSMA-617:

  • Indication: Metastatic castration-resistant prostate cancer (mCRPC). Clinical Evidence:
  • REALITY Study: In 6 patients with inadequate response to [177 Lu] Lu-PSMA-617, [161Tb]Tb- PSMA-617 delivered higher tumor-absorbed doses, suggesting enhanced therapeutic efficacy. A case report demonstrated a 53% PSA decline after administration of 6.5 GBq of [161Tb]Tb- PSMA-617 to a patient whose disease had progressed after 8 cycles of [177 Lu] Lu-PSMA-617. VIOLET Trial: A Phase I/II trial evaluating the safety and efficacy of [161Tb]Tb-PSMA-I&T in patients with mCRPC.

[161Tb]Tb-DOTA-LM3:

  • Indication: Advanced neuroendocrine tumors (NETs).
  • Preclinical Findings: Studies have shown that 161Tb-labeled DOTA-LM3 exhibits superior tumor growth inhibition compared to its 177 Lu-labeled counterpart, suggesting enhanced therapeutic efficacy.

Emerging Radionuclide Therapy Available At Rnm Center:

LUTETIUM-177 FAPI (FIBROBLAST ACTIVATION PROTEIN INHIBITOR) THERAPY

An emerging radioligand treatment targeting cancer-associated fibroblasts (CAFs) prevalent in the tumor microenvironment of various solid tumors. Indications:

Indications:

An emerging radioligand treatment targeting cancer-associated fibroblasts (CAFs) prevalent in the tumor microenvironment of various solid tumors.
Indications:

  • Various solid tumors with high FAP expression on FAPI PET-CT with limited treatment options. Clinical Trials:

Clinical Trials:

177Lu-FAP-2286 (LUMIERE Study - NCT04939610):

  • Indications: Advanced solid tumors, including pancreatic ductal adenocarcinoma, non- small cell lung cancer, breast cancer.
  • Patient Selection: Positive 68Ga-FAP PET/CT scan indicating high FAP expression.
  • Patient Selection: Positive 68Ga-FAP PET/CT scan indicating high FAP expression. Administration: Initial dosing every 6 weeks, up to 6 doses.

Terbium-161 (161Tb) Radionuclide Therapies

Terbium-161 is an emerging radionuclide offering enhanced efficacy due to its emission of beta particles and Auger electrons, particularly effective in damaging micrometastases.

Lutetium-177 Dotatate Therapy:

Indications:

  • FDA Approved (2018) for GEP-NETS post SSA failure
  • Emerging first-line therapy for high-proliferation NETS (Grade 2-3)

Supporting Trials:

NETTER-1 Trial (NEJM 2017)

  • 79% improvement in PFS for midgut NETs

NETTER-2 Trial (2024, NEJM)

  • Evaluated Lutathera as first-line in Grade 2/3 GEP-NETS
  • Median PFS: 22.8 vs 8.5 months (Lutathera + SSA vs SSA alone)
  • Higher response rate and better symptom control

Patient Selection:

  • Positive SSTR imaging (Ga-68 DOTA PET)
  • Well-differentiated Grade 1-3 GEP-NETS
  • Considered in 1st line for high-grade tumors or post SSA progression

Radioiodine Therapy (I-131)

Low Dose Radioiodine Therapy Indications:

  • Hyperthyroidism ,
  • Toxic Nodular Goiter,
  • Autonomously functioning thyroid cancer)
  • Remnant ablation for thyroid cancer
  • Graves'

High Dose Radioiodine Therapy Indications

  • Differentiated thyroid cancer (DTC) – adjuvant, or metastatic- nodal, pulmonary and
    skeletal metastasis disease

Guidelines:

  • Recommended by ATA and ESMO for low/intermediate and high risk differentiated thyroid cancer
  • FDA-approved for thyroid cancer since 1950s Patient Selection:

Patient Selection:

  • Hyperthyroidism unresponsive to antithyroid drugs or can be used in first line setting as
    well.
  • Post-thyroidectomy DTC with residual or metastatic iodine-avid lesions

Radioiodine Complete Response: Nodal, Pulmonary And Skeletal Metastasis

61y/ F total thyroidectomy and central neck dissection; post left femoral resection and endoprosthesis reconstruction on 01-07-22 HPE- residual follicular carcinoma in left lobe of thyroid, LN -ve; metastatic follicular carcinoma of thyroid

Call Now Button